ArticleFrontiers in genetics2025
Integrated network toxicology, machine learning algorithms and TMT proteomics reveal the mechanism of 18β glycyrrhetinic acid against gastric cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this paper is to explore the mechanism of 18β glycyrrhetinic acid (18β-GRA) in treating gastric cancer. Firstly, the toxicological effects of 18β-GRA were predicted using the ProTox3.0 database. Then, candidate biomarkers for the anti-gastric cancer of 18β-GRA were screened using the weighted gene co-expression network analysis (WGCNA), the least absolute shrinkage and selection operator (LASSO), the support vector machine (SVM), the random forest algorithm combined with the TMT proteomics methods. Additionally, we explored the potential upstream transcription factors and downstream interacting proteins of the biomarkers. The WGCNA method yielded 269 targets, while TMT proteomics analysis identified 6,273 genes. Among these, 12 targets were identical. Using LASSO, SVM, and random forest algorithms, three candidate markers were identified: insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), keratin 6B (KRT6B), and E3 ubiquitin-protein ligase NEDD4-like (NEDD4L). Based on molecular docking and molecular dynamics results, NEDD4L is believed to be a 18β-GRA biomarker, while sodium channel protein type 5 subunit alpha (SCN5A) and early growth response protein 1 (EGR1) are the potential upstream and downstream regulatory proteins, respectively. These findings provide a theoretical basis for future experimental verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.